Aerosol Immunotherapy with or without Cisplatin for metastatic lung cancer non-small cell lung cancer disease: In vivo Study. A more efficient combination
| Autor: | Wolfgang Hohenforst-Schmidt, Ilias Karapantzos, Li Wang, Dimitrios Giannakidis, Athanasios Katsaounis, Paul Zarogoulidis, Konstantinos Sapalidis, Haidong Huang, Charilaos Koulouris, Efstathios T Pavlidis, Chong Bai, Fotis Konstantinou, Aikaterini Amaniti, Chrysanthi Karapantzou, Yuting Wen, Isaak Kesisoglou, Chrysanthi Sardeli, Stella Laskou, Stylianos Mantalovas, Naim Benhanseen |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
programmed death-ligand 1 aerosol medicine.medical_treatment Ipilimumab Pembrolizumab NSCLC 03 medical and health sciences Prostate cancer 0302 clinical medicine Breast cancer medicine ipilimumab Lung cancer Cisplatin nivolumab business.industry Immunotherapy medicine.disease lung cancer 030104 developmental biology Oncology 030220 oncology & carcinogenesis Cancer research immunotherapy pembrolizumab Nivolumab business medicine.drug Research Paper |
| Zdroj: | Journal of Cancer |
| ISSN: | 1837-9664 |
| Popis: | Lung cancer is the leading cause of cancer death after prostate cancer for males and breast cancer for females. There are novel therapies in the past five years such as; tyrosine kinase inhibitors and most recently in the last two years immunotherapy. Immunotherapy is currently being investigated if it can be administered alone or in combination. Previously we have investigated whether immunotherapy compounds can be produced as aerosols, and in the current study we investigated the safety and efficiency independently of the programmed death-ligand 1. The aerosol administration of both cisplatin and nivolumab is possible. The combination of the two drugs has a synergistic effect and therefore should be considered an option. Time of administration for immunotherapy is also very important. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|